Is It Time To Reassess Amgen (AMGN) After Its Strong Multi Year Share Price Run
- If you are wondering whether Amgen at around US$324.39 is still offering value after a solid run, this article walks through what the current price really implies.
- The stock is down 1.6% over the past week and 8.7% over the past month, yet it is still up 1.0% year to date and 21.1% over the past year, with 3 year and 5 year returns of 58.8% and 53.3% respectively. This naturally raises questions about how much of its potential is already in the price.
- Recent headlines around Amgen have focused on its role as a large US biotech and how it fits into portfolios that are looking at healthcare exposure, which helps explain some of the shifts in sentiment reflected in the share price. Broader discussions about regulation, drug pipelines and…
Source link
